Puma Biotechnology Current Valuation
| PBYI Stock | USD 6.79 0.31 4.37% |
Valuation analysis of Puma Biotechnology helps investors to measure Puma Biotechnology's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of now, Puma Biotechnology's Enterprise Value Over EBITDA is increasing as compared to previous years. The Puma Biotechnology's current Enterprise Value Multiple is estimated to increase to 3.01, while Enterprise Value is projected to decrease to under 167.4 M. Fundamental drivers impacting Puma Biotechnology's valuation include:
Overvalued
Today
Please note that Puma Biotechnology's price fluctuation is moderately volatile at this time. Calculation of the real value of Puma Biotechnology is based on 3 months time horizon. Increasing Puma Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Puma Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Puma Stock. However, Puma Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.79 | Real 5.74 | Target 5.0 | Hype 7.03 | Naive 7.04 |
The intrinsic value of Puma Biotechnology's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Puma Biotechnology's stock price.
Estimating the potential upside or downside of Puma Biotechnology helps investors to forecast how Puma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Puma Biotechnology more accurately as focusing exclusively on Puma Biotechnology's fundamentals will not take into account other important factors: Puma Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Puma Biotechnology is extremely important. It helps to project a fair market value of Puma Stock properly, considering its historical fundamentals such as Current Valuation. Since Puma Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Puma Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Puma Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.71 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Puma Biotechnology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Puma Biotechnology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Puma Biotechnology.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Puma Biotechnology on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Puma Biotechnology or generate 0.0% return on investment in Puma Biotechnology over 90 days. Puma Biotechnology is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, OSR Holdings, Lipocine, and SeaStar Medical. Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to e... More
Puma Biotechnology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Puma Biotechnology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Puma Biotechnology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.68 | |||
| Information Ratio | 0.1069 | |||
| Maximum Drawdown | 43.28 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 5.25 |
Puma Biotechnology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Puma Biotechnology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Puma Biotechnology's standard deviation. In reality, there are many statistical measures that can use Puma Biotechnology historical prices to predict the future Puma Biotechnology's volatility.| Risk Adjusted Performance | 0.0961 | |||
| Jensen Alpha | 0.5123 | |||
| Total Risk Alpha | 0.3149 | |||
| Sortino Ratio | 0.1061 | |||
| Treynor Ratio | 0.9722 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Puma Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Puma Biotechnology February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0961 | |||
| Market Risk Adjusted Performance | 0.9822 | |||
| Mean Deviation | 2.69 | |||
| Semi Deviation | 4.17 | |||
| Downside Deviation | 4.68 | |||
| Coefficient Of Variation | 857.35 | |||
| Standard Deviation | 4.64 | |||
| Variance | 21.55 | |||
| Information Ratio | 0.1069 | |||
| Jensen Alpha | 0.5123 | |||
| Total Risk Alpha | 0.3149 | |||
| Sortino Ratio | 0.1061 | |||
| Treynor Ratio | 0.9722 | |||
| Maximum Drawdown | 43.28 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 5.25 | |||
| Downside Variance | 21.89 | |||
| Semi Variance | 17.36 | |||
| Expected Short fall | (3.05) | |||
| Skewness | 0.1091 | |||
| Kurtosis | 13.31 |
Puma Biotechnology Backtested Returns
Puma Biotechnology appears to be moderately volatile, given 3 months investment horizon. Puma Biotechnology maintains Sharpe Ratio (i.e., Efficiency) of 0.0734, which implies the firm had a 0.0734 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Puma Biotechnology, which you can use to evaluate the volatility of the company. Please evaluate Puma Biotechnology's Risk Adjusted Performance of 0.0961, coefficient of variation of 857.35, and Semi Deviation of 4.17 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Puma Biotechnology holds a performance score of 5. The company holds a Beta of 0.55, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Puma Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Puma Biotechnology is expected to be smaller as well. Please check Puma Biotechnology's maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to make a quick decision on whether Puma Biotechnology's historical price patterns will revert.
Auto-correlation | 0.54 |
Modest predictability
Puma Biotechnology has modest predictability. Overlapping area represents the amount of predictability between Puma Biotechnology time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Puma Biotechnology price movement. The serial correlation of 0.54 indicates that about 54.0% of current Puma Biotechnology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.54 | |
| Spearman Rank Test | 0.59 | |
| Residual Average | 0.0 | |
| Price Variance | 0.13 |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Puma Biotechnology has a Current Valuation of 304.94 M. This is 97.88% lower than that of the Biotechnology sector and 93.44% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.17% higher than that of the company.
Puma Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Puma Biotechnology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Puma Biotechnology could also be used in its relative valuation, which is a method of valuing Puma Biotechnology by comparing valuation metrics of similar companies.Puma Biotechnology is currently under evaluation in current valuation category among its peers.
Puma Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Puma Biotechnology from analyzing Puma Biotechnology's financial statements. These drivers represent accounts that assess Puma Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Puma Biotechnology's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 123.5M | 189.0M | 204.1M | 148.4M | 170.6M | 162.1M | |
| Enterprise Value | 177.1M | 227.1M | 231.0M | 153.2M | 176.2M | 167.4M |
Puma Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Puma Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Puma Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Puma Fundamentals
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.099 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 304.94 M | ||||
| Shares Outstanding | 50.39 M | ||||
| Shares Owned By Insiders | 15.38 % | ||||
| Shares Owned By Institutions | 71.46 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | 18.52 X | ||||
| Price To Book | 3.11 X | ||||
| Price To Sales | 1.61 X | ||||
| Revenue | 230.47 M | ||||
| Gross Profit | 163.04 M | ||||
| EBITDA | 48.08 M | ||||
| Net Income | 30.28 M | ||||
| Cash And Equivalents | 77.96 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 74.08 M | ||||
| Debt To Equity | 5.19 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | 2.29 X | ||||
| Cash Flow From Operations | 38.92 M | ||||
| Short Ratio | 9.67 X | ||||
| Earnings Per Share | 0.71 X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 172 | ||||
| Beta | 1.23 | ||||
| Market Capitalization | 342.16 M | ||||
| Total Asset | 213.33 M | ||||
| Retained Earnings | (1.31 B) | ||||
| Working Capital | 51.55 M | ||||
| Current Asset | 223.55 M | ||||
| Current Liabilities | 32.44 M | ||||
| Net Asset | 213.33 M |
About Puma Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Puma Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Puma Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Puma Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.71 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.